$ITRG

Integra study boosts Florida Canyon mine life

Integra Resources updated the feasibility study for its Florida Canyon gold mine in Nevada, reporting a 74% rise in mineral reserves to 1.19 million oz and higher expected production (70,000 to 82,000 oz/year). After-tax NPV is $601M at base metal prices and $723M at spot prices. The company expects $800M free cash flow over eight years and revised 2026 AISC to $3,300–$3,500/oz.

Original reporting
Published Jul 3, 2026, 1:00 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jul 3, 2026, 1:09 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Integra study boosts Florida Canyon mine life — source image
Decision brief

The 30-second read

$ITRGBullishMed
01

Why it matters

The update materially changes the mine’s economics (NPV, reserves, production rate) and revises 2026 cost guidance upward, while reiterating that Florida Canyon cash flow will fund advancement of DeLamar and Nevada North.

02

Market read

Traders can reassess ITRG’s cash-generation trajectory and funding runway based on the updated reserve/prod outlook and the explicit 2026 cost guidance revision.

03

What to watch

The plan relies on assumptions for metal prices, production ramp to 82k oz/yr, and heap-leach performance; any deviation in recovery rates or capex execution could reduce the projected free-cash-flow and self-funding capacity.

Relevance 7/10Novelty 7/10Timing: post-release of updated Florida Canyon feasibility study and 2026 cost guidance

Background

Integra Resources updated the feasibility study and life-of-mine plan for its Florida Canyon gold mine in Nevada, including reserve/prod changes and revised cost assumptions.

Company-level read

Ticker impact

$ITRGBullishMedium confidence
Context

Integra released an updated Florida Canyon feasibility study showing a 74% reserve increase, higher production, and revised 2026 cost guidance.

Expected impact

Moderately positive bias for ITRG as investors price in higher reserve life, production ramp, and self-funding capacity; near-term volatility possible due to higher 2026 AISC.

Evidence & confidence

The article provides multiple concrete, decision-relevant datapoints (reserve/prod changes, NPV under base/spot, free-cash-flow estimate, and a specific AISC guidance revision) tied directly to ITRG’s only producing asset and its funding plan.

Market effects

Supports read-across for US gold heap-leach operators: improved reserve life and economics can attract capital, while higher diesel/explosives inflation highlights cost sensitivity.

Limited direct regional impact beyond Nevada mining sentiment; DeLamar permitting progress could matter for Idaho/Western US precious-metals development sentiment.

Gold-price assumptions and NPV sensitivity reinforce how global gold moves translate into US producer cash flows, but the catalyst is company-specific.

Counterpoint

Higher 2026 all-in sustaining costs (revised upward) could pressure margins and near-term free cash flow despite the longer mine life, making the market focus on execution risk rather than headline NPV.

Key entities

  • Integra Resources Corp.

    Owner/operator of Florida Canyon; released updated feasibility study and mine life plan and revised 2026 AISC guidance.

  • Florida Canyon Mine

    Integra’s Nevada producing heap-leach gold mine; updated plan increases reserves and expected annual production.

  • DeLamar Project (BLM permitting)

    Idaho project whose permitting record of decision is expected in Q2 next year; funded via Florida Canyon cash flow.

  • Nevada North Project

    West of Florida Canyon; advancement supported by Florida Canyon cash flow.

Related articles

$ITRGMedAI 8/10

Integra Resources (ITRG) Q2 2026 Earnings Call Transcript

Integra Resources (ITRG) reported Q2 2026 earnings with record gold production (16.4K oz), revenue ($70.8M), and operating cash flow ($22.8M). The company maintained annual gold production guidance (70K-75K oz). Florida Canyon's updated life of mine plan shows increased reserves, extended mine life, and improved cash flow. DeLamar project advances through federal permitting.

$ITRGMedAI 8/10

INTEGRA REPORTS SECOND QUARTER 2026 RESULTS; 30% INCREASE IN QUARTERLY GOLD PRODUCTION, RECORD TOTAL TONNES MINED AND STRENGTHENED FINANCIAL POSITION

Integra Resources Corp. reported Q2 2026 results for the three months ended June 30, 2026. Gold production at Florida Canyon rose 30% quarter over quarter to 16,379 oz, with revenue of $70.8 million and adjusted earnings of $13.1 million ($0.06/share). Cash and cash equivalents were $111.1 million. The company reiterated full-year guidance of 70,000 to 75,000 oz and filed an updated Florida Canyon feasibility study.

$ITRGMed

INTEGRA FILES FEASIBILITY STUDY AND UPDATED LIFE OF MINE PLAN TECHNICAL REPORT FOR THE PRODUCING FLORIDA CANYON MINE

TSXV: ITR; NYSE American: ITRG www.integraresources.com VANCOUVER, BC, July 30, 2026 /PRNewswire/ -- Integra Resources Corp. ("Integra" or the "Company") (TSXV: ITR) (NYSE American: ITRG) is pleased to announce that, further to its news release dated June 25, 2026, it has filed a Feasibility Study Technical Report and updated Life of Mine Plan (the "Technical Report") for the operating Florida Canyon Mine ("Florida Canyon" or the "Mine"), located in Pershing County, Nevada.

$NVDALowAI 8/10

NVIDIA's $99 Billion AI Portfolio: Every Major Investment in 2026

NVIDIA's equity investments in AI companies totaled $99 billion, up from $7 billion a year ago. Key investments include OpenAI ($30B), Hugging Face ($12.9B), and Anthropic ($10B). The company's Q2 2027 revenue was $96.2B, up 106% YoY, with data center revenue at $89B, up 117%. NVIDIA is also involved in $500B in AI infrastructure financing. Investments aim to secure customers, create dependencies, and gain equity upside, but also expose NVIDIA to market risks and potential regulatory scrutiny.

$CYTKMedAI 8/10

Could Aficamten Give Cytokinetics the First Approved nHCM Treatment?

Cytokinetics (NASDAQ:CYTK) reported late-stage trial results for aficamten in non-obstructive hypertrophic cardiomyopathy (nHCM), meeting primary goals of improving symptoms and quality of life. The study showed 53% of patients on aficamten improved in key areas vs. 13% on placebo, but lacked significant structural or cardiovascular benefits. The company plans a US marketing application in Q4 2026. Analysts forecast peak sales of over $5 billion for Myqorzo, but investors expressed concerns over

$CCJMed

Jefferies Sees Cameco (CCJ) and BWXT as Winners in the Nuclear Boom

Jefferies initiated coverage of Cameco (CCJ) and BWXT (BWXT) with 'Buy' ratings, setting price targets of $138 and $181 respectively, citing strong long-term prospects in nuclear energy. CCJ, a major uranium producer, and BWXT, a nuclear reactor provider, are positioned to benefit from global and U.S. initiatives to expand nuclear capacity. Both companies face risks, including uranium price volatility for CCJ and execution challenges for BWXT.